Imagine being able to mathematically compute the entire process by which an embryo develops into an animal. Such a capability holds enormous promise for medicine, pointing to the potential for determining when and where development can go awry, and paving the way to possible solutions.
After an announcement by federal officials approving clinical trials for the drug Crenezumab, researchers searching for a way to treat Alzheimer’s Disease are gearing up for a rare study that will allow them to test a therapy for a genetically predestined disease - before its onset.
UC Santa Barbara researchers have discovered Salmonella bacteria that are up to 100 times more capable of causing disease. Their findings may help prevent food poisoning outbreaks that continue to plague public health and the food industry.
What if bacteria could talk to each other? What if they had a sense of touch? A new study by researchers at UC Santa Barbara suggests both, and theorizes that such cells may, in fact, need to communicate in order to perform certain functions. The findings appear today in the journal Genes & Development.
Pete Coffey, an internationally prominent researcher from Britain who works on stem cell biology and the prevention of blindness, will direct UCSB's Center for the Study of Macular Degeneration, and will also work with the university's Center for Stem Cell Biology and Engineering. Both centers are part of UCSB's Neuroscience Research Institute. The California Institute for Regenerative Medicine provided a grant to recruit Coffey, who is currently the director of the London Project to Cure Blindness at the University College of London.
Scientists Make Strides Toward Drug Therapy for Inherited Kidney Disease Research in the laboratory of Thomas Weimbs in MCDB has led to the discovery that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.
MCDB scientist in collaboration with Sanford-Burnham and Salk Institute scientists combine tumor-targeting peptides and nanoparticles to eliminate glioblastoma in a previously untreatable mouse model. In a study published the week of October 3 in the Proceedings of the National Academy of Sciences of the USA, a team of scientists led by Dr. Ruoslahti, combined a tumor-homing peptide, a cell-killing peptide, and a nanoparticle.
Newly diagnosed Type 2 diabetics tend to have one thing in common: obesity. Exactly how diet and obesity trigger diabetes has long been the subject of intense scientific research. A new study led by Jamey D. Marth, director of the Center for Nanomedicine, a collaboration between the University of California, Santa Barbara and Sanford-Burnham Medical Research Institute (Sanford-Burnham), has revealed a pathway that links high-fat diets to a sequence of molecular events responsible for the onset and severity of diabetes.
MCDB is proud to announce the establishment of an Emphasis in Pharmacology and Biotechnology within the M.A. degree. The proposal for the new degree was approved last week by the Graduate Council and Letters and Science Executive Committee. The new interdisciplinary Master's Emphasis is designed to take advantage of the many interdisciplinary opportunities in the fields of pharmacology and biotechnology on the UCSB campus. Students have the option of enrolling in a wide variety of courses offered through three UCSB departments, MCDB, Chemistry and Biochemistry, and Psychology.
Research from the laboratory of Thomas Weimbs in MCDB points to potential new drug therapies for patients with polycystic kidney disease. The findings, implicating the transcription factor STAT3 as a promising drug target, are published in this week's issue of the Proceedings of the National Academy of Sciences.